1. Home
  2. UAA vs HRMY Comparison

UAA vs HRMY Comparison

Compare UAA & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Under Armour Inc.

UAA

Under Armour Inc.

HOLD

Current Price

$7.13

Market Cap

2.6B

ML Signal

HOLD

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$35.74

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UAA
HRMY
Founded
1996
2017
Country
United States
United States
Employees
14100
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.2B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
UAA
HRMY
Price
$7.13
$35.74
Analyst Decision
Hold
Buy
Analyst Count
16
9
Target Price
$6.48
$44.11
AVG Volume (30 Days)
7.1M
856.6K
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.97
EPS
N/A
0.55
Revenue
N/A
$868,453,000.00
Revenue This Year
N/A
$19.75
Revenue Next Year
$1.57
$12.88
P/E Ratio
N/A
$65.47
Revenue Growth
N/A
21.51
52 Week Low
$4.13
$25.52
52 Week High
$8.15
$40.87

Technical Indicators

Market Signals
Indicator
UAA
HRMY
Relative Strength Index (RSI) 60.14 52.85
Support Level $5.47 $35.05
Resistance Level $7.50 $39.07
Average True Range (ATR) 0.33 1.59
MACD -0.02 -0.10
Stochastic Oscillator 71.23 55.84

Price Performance

Historical Comparison
UAA
HRMY

About UAA Under Armour Inc.

Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and Latin America. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through wholesale partners, company-owned digital channels, and approximately 440 company-owned outlet and full-price stores. The Baltimore-based firm was founded in 1996 and is led by controlling shareholder Kevin Plank.

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Share on Social Networks: